The combination of sulfadiazine + trimethoprim (TMPS) act synergistically to kill a wide range of susceptible bacteria and reduces the possibility of bacterial resistance developing.
The combination blocks the synthesis of bacterial folates at two critical points, which are essential for bacterial cell multiplication and survival. The combination of sulfadiazine + trimethoprim is bactericidal, while either drug alone is bacteriostatic. Folate synthesizing bacteria which are resistant or moderately resistant to either drug alone are frequently susceptible to the combination.
Randlab’s TMPS Oral Paste has a broad spectrum of activity against the common Gram-positive and Gram-negative bacteria including Staphylococci (including S. aureus and some strains of MRSA), Streptococci, Dermatophilus congolensis, Escherichia coli, Bacillus, Bordetella, Brucella, Corynebacterium, Fusiformis, Hemophilus, Klebsiella spp, Listeria monocytogenes, Nocardia, Pasteurella, Salmonella, Shigella and Proteus spp. (including S, aureus and some strains of MRSA).
The combination also has some effect against infections caused by protozoa (eg coccidia and Toxoplasma infection)
Infections caused by Leptospira, Psuedomonas, Mycobacterium and Erysipelothrix are generally not susceptible.
Randlab’s TMPS Oral Paste is useful in the treatment of respiratory infections, with high lung tissue levels achieved (although Airways Tmps and Bromo Tmps are designed specifically for respiratory infections), soft tissue infections, abdominal infections, joint infections, infections of the CNS, urinary tract infections and infections of the uterus/ placenta.
The bactericidal properties of Randlab’s Tmps Oral Paste may be reduced in the presence of pus and therefore should not be used for treating abscesses or infections caused by anaerobic bacteria.
